Argent BioPharma (ASX: RGT) has confirmed that pharmaceutical manufacturer ECCPharm will take on full production and release responsibilities for Argent’s emerging cannabinoid therapies under a strategic partnership between the two companies.
The agreement will ensure the CannEpil and CogniCann treatments are available under early patient access programs in key European countries including Ireland, the UK and Germany.
Argent will retain ownership of all current and future research and development, as well as intellectual property rights, under the partnership.
A technology transfer will relocate the products’ official manufacturing base from Argent’s European facilities to ECCPharm’s state-of-the-art facility in North Macedonia at Argent’s expense.
The move aims to enhance production efficiency, ensure regulatory compliance and support scalable manufacturing to meet growing global patient demand for high-quality, medical cannabis-based pharmaceuticals.
The transfer process will commence immediately, with manufacturing at ECCPharm’s North Macedonian facility expected to begin in the coming months.
The strategic partnership will allow Argent to focus resources on the clinical development and medical advancement of new products.
It will also deliver operational cost reductions for Argent and minimise monthly cash flow burn from running its own manufacturing facilities within Europe.
“By leveraging ECCPharm’s manufacturing expertise, we will secure a scalable, cost-effective production platform for CannEpil and CogniCann,” Argent chief executive officer Roby Zomer said.
“It will allow us to concentrate on our core mission of advancing clinical development and expanding regulatory approvals worldwide.”
CannEpil is a clinically supported treatment for patients with refractory epilepsy who have not benefited from traditional anti-epileptic drugs.
After conducting human trials in Australia and gathering real-world data over the years, Argent expects CannEpil to be available under early patient access programs in key European markets.
CogniCann is an investigational therapy targeting various types of dementia including Alzheimer’s and Parkinson’s disease.
Early clinical trial results in Australia have indicated that use of the drug could deliver improvements in cognitive function, behaviour and overall patient well-being.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。